Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
Extraordinary outcomes are built on curiosity, creativity, and the relentless pursuit of smarter healthcare for all. Our breakthroughs power our solutions, supporting the needs of our partners – and their patients.
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
Extraordinary outcomes are built on curiosity, creativity, and the relentless pursuit of smarter healthcare for all. Our breakthroughs power our solutions, supporting the needs of our partners – and their patients.
En España, existen 18 moléculas biológicas que disponen de biosimilar. No obstante, el uso de biológico original o biosimilar es muy variable entre los diferentes países de Europa.
Actualmente encontramos 18 productos biosimilares que están en proceso de evaluación por parte de la EMA, y en los próximos 5 años, más de 30 productos biológicos van a perder su patente.
El uso de biosimilares en aquellos fármacos dispensados a través de la farmacia comunitaria es inferior a la de los fármacos dispensados a través de la farmacia hospitalaria. Además, encontramos diferencias en el uso del biosimilar o el biológico en función de la especialidad.
A nivel regional, el modelo de compra de la comunidad autónoma no parece ser una variable que por sí sola explique un mayor uso del fármaco original o del biosimilar. Probablemente otras variables como las estrategias de gestión de la provisión de cada comunidad pueden estar influenciando en este comportamiento.